This preclinical study therefore advocates that neutralizing antibodies be further tested against IL1β, IL6, or TNFα in clinical settings for managing the aseptic loosening of orthopedic prostheses and oral peri-implantitis. The gene discussed is IL6; the disease is Peri-Implantitis.